Published in J Gen Intern Med on July 01, 2003
Community-based participatory research: opportunities, challenges, and the need for a common language. J Gen Intern Med (2003) 2.37
Community-based participatory research in practice-based research networks. Ann Fam Med (2006) 2.04
Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med (2010) 1.69
Addressing poverty as risk for disease: recommendations from CDC's consultation on microenterprise as HIV prevention. Public Health Rep (2008) 1.41
Sustained reduction in tuberculosis incidence following a community-based participatory intervention. Public Health Action (2012) 0.77
An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med (1992) 13.29
Participatory research maximises community and lay involvement. North American Primary Care Research Group. BMJ (1999) 9.96
Using empowerment theory in collaborative partnerships for community health and development. Am J Community Psychol (1995) 3.16
Syphilis and AIDS in Belle Glade, Florida, 1942 and 1992. Ann Intern Med (1992) 2.98
Outbreak of multi-drug-resistant tuberculosis in a New York State prison, 1991. Am J Epidemiol (1994) 2.20
Tuberculosis in the homeless. A prospective study. Am J Respir Crit Care Med (2000) 1.71
Project community diagnosis: participatory research as a first step toward community involvement in primary health care. Soc Sci Med (1984) 1.55
Transmission of HIV in Belle Glade, Florida: lessons for other communities in the United States. Science (1988) 1.17
Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA (2006) 17.93
Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med (2011) 6.14
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis (2005) 4.45
Endothelial function in HIV-infected persons. Clin Infect Dis (2006) 3.80
The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS (2011) 3.35
Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis (2012) 2.38
Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med (2011) 2.36
The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med (2006) 2.33
Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med (2006) 2.23
HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr (2005) 2.13
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet (2002) 1.74
Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med (2010) 1.69
The menstrual cycle does not affect human immunodeficiency virus type 1 levels in vaginal secretions. J Infect Dis (2002) 1.67
Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol (2010) 1.56
Use of a population-based survey to describe the health of Boston public housing residents. Am J Public Health (2007) 1.47
Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med (2006) 1.45
The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS (2012) 1.40
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis (2013) 1.37
The associations of binge alcohol use with HIV/STI risk and diagnosis among heterosexual African American men. Drug Alcohol Depend (2008) 1.33
Randomized controlled trial of an intervention to prevent adherence failure among HIV-infected patients initiating antiretroviral therapy. Health Psychol (2008) 1.33
Environmental risk factors for infection with Mycobacterium avium complex. Am J Epidemiol (2006) 1.31
Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. AIDS (2003) 1.28
Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol (2013) 1.27
Treatment of Tuberculosis. N Engl J Med (2015) 1.25
Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS (2008) 1.25
A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis (2002) 1.14
Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. BMC Infect Dis (2008) 1.14
Human immunodeficiency virus infection in a rural community in the United States. Am J Epidemiol (2004) 1.12
Diabetes, glycemic control, and risk of tuberculosis: a population-based case-control study. Diabetes Care (2011) 1.11
Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clin Infect Dis (2004) 1.11
Antiretroviral therapy enrollment characteristics and outcomes among HIV-infected adolescents and young adults compared with older adults--seven African countries, 2004-2013. MMWR Morb Mortal Wkly Rep (2014) 1.10
History of incarceration and gang involvement are associated with recent sexually transmitted disease/HIV diagnosis in African American men. J Acquir Immune Defic Syndr (2008) 1.09
Social organization of sexual-economic networks and the persistence of HIV in a rural area in the USA. Cult Health Sex (2007) 1.06
Incidence and determinants of tuberculosis among adults initiating antiretroviral therapy--Mozambique, 2004-2008. PLoS One (2013) 1.02
Characteristics of HIV care and treatment in PEPFAR-supported sites. J Acquir Immune Defic Syndr (2011) 1.01
Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clin Infect Dis (2013) 1.00
Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. J Infect Dis (2010) 1.00
Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine (2010) 0.99
Risk of progression to active tuberculosis among foreign-born persons with latent tuberculosis. Chest (2007) 0.99
Predictors of failure to complete treatment for latent tuberculosis infection. J Infect (2006) 0.96
Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study. J Acquir Immune Defic Syndr (2014) 0.95
Risk factors for nonadherence with Pap testing in HIV-infected women. J Womens Health (Larchmt) (2011) 0.92
Recent cigarette smoking and HIV disease progression: no evidence of an association. AIDS Care (2011) 0.92
Extensively drug-resistant tuberculosis in women, KwaZulu-Natal, South Africa. Emerg Infect Dis (2011) 0.89
Factors associated with loss to follow-up in a large tuberculosis treatment trial (TBTC Study 22). Contemp Clin Trials (2006) 0.89
Hospital water as a source of Mycobacterium avium complex isolates in respiratory specimens. J Infect Dis (2003) 0.89
Using resident health advocates to improve public health screening and follow-up among public housing residents, Boston, 2007-2008. Prev Chronic Dis (2010) 0.89
Molecular epidemiology of HIV-associated tuberculosis in Dar es Salaam, Tanzania: strain predominance, clustering, and polyclonal disease. J Clin Microbiol (2012) 0.88
Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus coinfection. AIDS Patient Care STDS (2011) 0.87
Polyantigenic interferon-γ responses are associated with protection from TB among HIV-infected adults with childhood BCG immunization. PLoS One (2011) 0.86
Lower Levels of Antiretroviral Therapy Enrollment Among Men with HIV Compared with Women - 12 Countries, 2002-2013. MMWR Morb Mortal Wkly Rep (2015) 0.86
The GirlStars program: challenges to recruitment and retention in a physical activity and health education program for adolescent girls living in public housing. Prev Chronic Dis (2010) 0.86
Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. Clin Infect Dis (2012) 0.84
Reinfection with Mycobacterium tuberculosis. Am J Respir Crit Care Med (2006) 0.84
Evaluation of exposure-specific risks from two independent samples: a simulation study. BMC Med Res Methodol (2011) 0.84
Quality of hepatitis C care at an urban tertiary care medical center. J Health Care Poor Underserved (2014) 0.82
HIV/AIDS care and treatment in three provinces in northern Thailand before the national scale-up of highly-active antiretroviral therapy. Southeast Asian J Trop Med Public Health (2006) 0.82
Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial. J Infect Dis (2006) 0.81
Increased mortality associated with treated active tuberculosis in HIV-infected adults in Tanzania. Tuberculosis (Edinb) (2013) 0.81
Encouraging news for multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med (2010) 0.80
Predictors of active injection drug use in a cohort of patients infected with hepatitis C virus. Am J Public Health (2012) 0.79
Commentary on Greig et al, "Similar mortality and reduced loss to follow-up in integrated compared with vertical programs providing antiretroviral treatment in sub-Saharan Africa". J Acquir Immune Defic Syndr (2012) 0.79
Temporal trends in mortality and loss to follow-up among children enrolled in Côte d'Ivoire's national antiretroviral therapy program. Pediatr Infect Dis J (2014) 0.79
Effect of exposure to injection drugs or alcohol on antigen-specific immune responses in HIV and hepatitis C virus coinfection. J Infect Dis (2007) 0.79
Prevention of tuberculosis in older adults in the United States: obstacles and opportunities. Clin Infect Dis (2013) 0.79
Implementation and Operational Research: Evaluation of Swaziland's Hub-and-Spoke Model for Decentralizing Access to Antiretroviral Therapy Services. J Acquir Immune Defic Syndr (2015) 0.78
Decentralizing Access to Antiretroviral Therapy for Children Living with HIV in Swaziland. Pediatr Infect Dis J (2016) 0.78
Greater preexisting interferon γ responses to mycobacterial antigens and lower bacillary load during HIV-associated tuberculosis. J Infect Dis (2013) 0.76
Adolescent experiences of violence and relation to violence perpetration beyond young adulthood among an urban sample of Black and African American males. J Urban Health (2014) 0.76
A Decade of Antiretroviral Therapy Scale-up in Mozambique: Evaluation of Outcome Trends and New Models of Service Delivery Among More Than 300,000 Patients Enrolled During 2004-2013. J Acquir Immune Defic Syndr (2016) 0.76
Primary transmission of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected persons: what does the future hold in store? J Infect Dis (2008) 0.75
Another step on the path to better TB therapies. Int J Tuberc Lung Dis (2002) 0.75
Correction: Outcomes of Nigeria's HIV/AIDS Treatment Program for Patients Initiated on Antiretroviral Treatment between 2004-2012. PLoS One (2017) 0.75
Commentary: can mortality rates among adult antiretroviral therapy patients in Europe reach levels similar to those experienced in the general population? Int J Epidemiol (2012) 0.75
Temporal Trends in Patient Characteristics and Outcomes Among Children Enrolled in Mozambique's National Antiretroviral Therapy Program. Pediatr Infect Dis J (2015) 0.75
Evidence-based prevention of MDR-TB: an intervention whose time has come. Int J Tuberc Lung Dis (2010) 0.75
Real-world Outcomes of Hepatitis C Treatment during the Interferon-free Era at an Urban Safety-net Hospital. J Health Care Poor Underserved (2017) 0.75
Trends in Prevalence of Advanced HIV Disease at Antiretroviral Therapy Enrollment - 10 Countries, 2004-2015. MMWR Morb Mortal Wkly Rep (2017) 0.75
Predictors of treatment for hepatitis C virus (HCV) infection in drug users. Subst Abus (2008) 0.75